title: New approaches in systemic treatment of advanced colorectal cancer: the molecular targets era.
abstract: The prognosis of advanced colorectal cancer remains poor in spite of the advances obtained in recent years with new therapeutic agents, new approaches in surgical procedures and new diagnostic methods. New treatments directed to molecular targets have emerged and are being developed to improve these results, but there is a need to optimize and define the best use of these new approaches. In this review, the authors examine the most important trials with monoclonal antibodies and tyrosine kinase inhibitors in the treatment of advanced colorectal cancer.
authors.affiliation: Vall d'Hebron University Hospital, Medical Oncology Department, Barcelona, Spain. jacapdevila@vhebron.net
authors.forename: Jaume
authors.initials: J
authors.lastname: Capdevila
authors.forename: Guillermo
authors.initials: G
authors.lastname: Mendez
authors.forename: Teresa
authors.initials: T
authors.lastname: Macarulla
authors.forename: Francisco Javier
authors.initials: FJ
authors.lastname: Ramos
authors.forename: Esther
authors.initials: E
authors.lastname: Casado
authors.forename: Josep
authors.initials: J
authors.lastname: Tabernero
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000175:diagnosis / Q000556:secondary / Q000628:therapy*; D006801:Humans
chemical_list: D000970:Antineoplastic Agents